Interventions to reduce mortality in sub-Saharan Africa among HIV-infected adults not yet on antiretroviral therapy

References

• Braitstein P, Brinkhof MW, Dabis F et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet367(9513), 817–824 (2006).
   PubMed Web of Science ®Google Scholar
• Nakanjako D, Colebunders R, Coutinho AG, Kamya MR. Strategies to optimize HIV treatment outcomes in resource-limited settings. AIDS Rev.11(4), 179–189 (2009).
   PubMed Web of Science ®Google Scholar
• Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr. Opin. HIV AIDS5(1), 18–26 (2010).
   PubMed Web of Science ®Google Scholar
• Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med.8(7), e1001056 (2011).
   PubMed Web of Science ®Google Scholar
• Siegfried N, Uthman OA, Rutherford GW. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults. Cochrane Database Syst. Rev.3, CD008272 (2010).
   PubMed Web of Science ®Google Scholar
• Manabe YC, Campbell JD, Sydnor E, Moore RD. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J. Acquir. Immu. Defic. Syndr.46(4), 456–462 (2007).
   PubMed Web of Science ®Google Scholar
• Leisegang R, Cleary S, Hislop M et al. Early and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysis. PLoS Med.6(12), e1000189 (2009).
   Google Scholar
• Boothroyd J. World Health Organization. Dept. of HIV/AIDS. Essential prevention and care interventions for adults and adolescents living with HIV in resource-limited settings. World Health Organization, Geneva, Switzerland (2008).
   Google Scholar
• World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach – 2010 revision. World Health Organization, Geneva, Switzerland (2010).
   Google Scholar
• Myatt C, Givens M, Ives J et al. Low-cost imaging cytometer for point-of-care CD4+ cell counting. Low-cost imaging cytometer for point-of-care CD4+ cell counting. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 17–20 July 2011.
   Google Scholar
• Henkel T, Gohde R, Ost V, Gohde W. True point-of-care CD4/CD4% testing with highest accuracy and precision. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 17–20 July 2011.
   Google Scholar
• Sukapirom K, Onlamoon N, Thepthai C, Polsrila K, Tassaneetrithep B, Pattanapanyasat K. Performance evaluation of the Alere PIMA CD4 test for monitoring HIV-infected individuals in resource-constrained settings. J. Acquir. Immu. Defic. Syndr.58(2), 141–147 (2011).
   PubMedGoogle Scholar
• Faal M, Naidoo N, Glencross DK, Venter WD, Osih R. Providing immediate CD4 count results at HIV testing improves ART initiation. J. Acquir. Immu. Defic. Syndr.58(3), e54–e59 (2011).
   PubMed Web of Science ®Google Scholar
• Tayler-Smith K, Zachariah R, Massaquoi M et al. Unacceptable attrition among WHO Stages 1 and 2 patients in a hospital-based setting in rural Malawi: can we retain such patients within the general health system? Trans. R. Soc. Trop. Med. Hyg.104(5), 313–319 (2010).
   PubMedGoogle Scholar
• Boyles TH, Wilkinson LS, Leisegang R, Maartens G. Factors influencing retention in care after starting antiretroviral therapy in a rural South African programme. PLoS One6(5), e19201 (2011).
   Web of Science ®Google Scholar
• Lessells RJ, Mutevedzi PC, Cooke GS, Newell ML. Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu-Natal, South Africa. J. Acquir. Immu. Defic. Syndr.56(3), e79–e86 (2011).
   PubMed Web of Science ®Google Scholar
• Kohler PK, Chung MH, Mcgrath CJ, Benki-Nugent SF, Thiga JW, John-Stewart GC. Implementation of free cotrimoxazole prophylaxis improves clinic retention among ART-ineligible clients in Kenya. AIDS25(13), 1657–1661 (2011).
   PubMed Web of Science ®Google Scholar
• Togun T, Peterson I, Jaffar S et al. Pre-treatment mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy in The Gambia, West Africa. AIDS Res. Ther.8(1), 24 (2011).
   PubMedGoogle Scholar
• Lubega M. Lost in transition: pre-antiretroviral care and delayed initiation of antiretroviral therapy in Uganda. Thesis. Co-published by Makere University (Kampala, Uganda) and the Karolinska Institutet (Stockholm, Sweden), May 11 2011.
   Google Scholar
• Mcguire M, Munyenyembe T, Szumilin E et al. Vital status of pre-ART and ART patients defaulting from care in rural Malawi. Trop. Med. Int. Health15(Suppl. 1), 55–62 (2010).
   PubMed Web of Science ®Google Scholar
• Nilsson Schonnesson L, Ross MW, Bergbrant IM. Coping modes with HIV disease predict loss from HIV study cohort. Int. J. STD AIDS16(7), 479–481 (2005).
   PubMedGoogle Scholar
• Mahendra VS, Gilborn L, Bharat S et al. Understanding and measuring AIDS-related stigma in health care settings: a developing country perspective. Sahara J.4(2), 616–625 (2007).
   PubMedGoogle Scholar
• Brinkhof MW, Dabis F, Myer L et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull. World Health Organ.86(7), 559–567 (2008).
   PubMed Web of Science ®Google Scholar
• Zachariah R, Ford N, Philips M et al. Task shifting in HIV/AIDS: opportunities, challenges and proposed actions for sub-Saharan Africa. Trans. R. Soc. Trop. Med. Hyg.103(6), 549–558 (2009).
   PubMed Web of Science ®Google Scholar
• Nash DWY, Elul B, Hoos D, El Sadr W. For the international center for aids care and treatment programs (Icap). Program- and contextual-level determinants of low median CD4+ cell count in cohorts of persons initiating ART in 8 sub-Saharan African countries. AIDS25(12), 1523–1533 (2011).
   PubMedGoogle Scholar
• Tweya H, Gareta D, Chagwera F et al. Early active follow-up of patients on antiretroviral therapy (ART) who are lost to follow-up: the ‘Back-to-Care’ project in Lilongwe, Malawi. Trop. Med. Int. Health15(Suppl. 1), S82–S89 (2010).
   PubMed Web of Science ®Google Scholar
• Thomson KA, Cheti EO, Reid T. Implementation and outcomes of an active defaulter tracing system for HIV, prevention of mother to child transmission of HIV (PMTCT), and TB patients in Kibera, Nairobi, Kenya. Trans. R. Soc. Trop. Med. Hyg.105(6), 320–326 (2011).
   PubMed Web of Science ®Google Scholar
• Do NT, Phiri K, Bussmann H, Gaolathe T, Marlink RG, Wester CW. Psychosocial factors affecting medication adherence among HIV-1 infected adults receiving combination antiretroviral therapy (cART) in Botswana. AIDS Res. Hum. Retrovir.26(6), 685–691 (2010).
   PubMed Web of Science ®Google Scholar
• Protopopescu C, Raffi F, Roux P et al. Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias nduced by missing data. J. Antimicrob. Chemother.64(3), 599–606 (2009).
   PubMed Web of Science ®Google Scholar
• Peterson I, Togun O, de Silva T et al. Mortality and immuno-virological outcomes on antiretroviral therapy in HIV-1 and HIV-2 infected individuals in the Gambia, West Africa. AIDS25(17), 2167–2175 (2011).
   PubMed Web of Science ®Google Scholar
• Ware NC, Idoko J, Kaaya S et al. Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med.6(1), e11 (2009).
   PubMed Web of Science ®Google Scholar
• Obermeyer CM, Baijal P, Pegurri E. Facilitating HIV disclosure across diverse settings: a review. Am. J. Pub. Health101(6), 1011–1023 (2011).
   PubMed Web of Science ®Google Scholar
• Landon BE, Wilson IB, Mcinnes K et al. Physician specialization and the quality of care for human immunodeficiency virus infection. Arch. Intern. Med.165(10), 1133–1139 (2005).
   PubMed Web of Science ®Google Scholar
• Fatti G, Grimwood A, Bock P. Better antiretroviral therapy outcomes at primary healthcare facilities: an evaluation of three tiers of ART services in four South African provinces. PLoS One5(9), e12888 (2010).
   Google Scholar
• Apaka C. Correlates of missed visits by participants enrolled in an HIV prevention clinical trial in Eldoret, Kenya. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 17–20 July 2011.
   Google Scholar
• Brennan A, Long L, Maskew M et al. Outcomes of stable HIV-positive patients down-referred from doctor-managed antiretroviral therapy clinics to nurse-managed primary health clinics for monitoring and treatment. AIDS25(16), 2027–2036 (2011).
   PubMedGoogle Scholar
• Cooke GS, Tanser FC, Barnighausen TW, Newell ML. Population uptake of antiretroviral treatment through primary care in rural South Africa. BMC Pub. Health10, 585 (2010).
   PubMed Web of Science ®Google Scholar
• Massaquoi M, Zachariah R, Manzi M et al. Patient retention and attrition on antiretroviral treatment at district level in rural Malawi. Trans. R. Soc. Trop. Med. Hyg.103(6), 594–600 (2009).
   PubMed Web of Science ®Google Scholar
• Gardner EM, Mclees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin. Infect. Dis.52(6), 793–800 (2011).
   PubMed Web of Science ®Google Scholar
• Wanyenze RK, Hahn JA, Liechty CA et al. Linkage to HIV care and survival following inpatient HIV counseling and testing. AIDS Behav.15(4), 751–760 (2011).
   PubMed Web of Science ®Google Scholar
• Van Rie A, Sabue M, Jarrett N et al. Counseling and testing TB patients for HIV: evaluation of three implementation models in Kinshasa, Congo. Int. J. Tuberc. Lung Dis.12(3 Suppl. 1), S73–S78 (2008).
   PubMed Web of Science ®Google Scholar
• Marcellin F, Abe C, Loubiere S et al. Delayed first consultation after diagnosis of HIV infection in Cameroon. AIDS23(8), 1015–1019 (2009).
   PubMedGoogle Scholar
• Elbireer S, Guwatudde D, Mudiope P, Nabbuye-Sekandi J, Manabe YC. Tuberculosis treatment default among HIV-TB co-infected patients in urban Uganda. Trop. Med. Int. Health doi:10.1111/j.1365-3156.2011.02800.x. (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• World Health Organization. Stop TB Dept., UNAIDS, PEPFAR. A guide to monitoring and evaluation for collaborative TB/HIV activities. World Health Organization, Geneva, Switzerland (2009).
   Google Scholar
• Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS22(15), 1897–1908 (2008).
   PubMed Web of Science ®Google Scholar
• Cox JA, Lukande RL, Lucas S, Nelson AM, Van Marck E, Colebunders R. Autopsy causes of death in HIV-positive individuals in sub-Saharan Africa and correlation with clinical diagnoses. AIDS Rev.12(4), 183–194 (2010).
   PubMed Web of Science ®Google Scholar
• Reynolds S, Makumbi F, Kiwanuka N et al. Impact of HSV-2 suppressive therapy with daily acyclovir on HIV-1 disease progression: a randomized placebo-controlled trial in Rakai, Uganda. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 17–20 July 2011.
   Google Scholar
• Ludema C, Cole SR, Poole C, Chu H, Eron JJ. Meta-analysis of randomized trials on the association of prophylactic acyclovir and HIV-1 viral load in individuals coinfected with herpes simplex virus-2. AIDS25(10), 1265–1269 (2011).
   PubMed Web of Science ®Google Scholar
• Cain KP, Mccarthy KD, Heilig CM et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N. Engl. J. Med.362(8), 707–716 (2010).
   PubMed Web of Science ®Google Scholar
• Getahun H, Kittikraisak W, Heilig CM et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med.8(1), e1000391 (2011).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. World Health Organization, Geneva, Switzerland (2011).
   Google Scholar
• World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational ‘How-to’; practical considerations. World Health Organization, Geneva, Switzerland (2011).
   Google Scholar
• Boehme CC, Nicol MP, Nabeta P et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet377(9776), 1495–1505 (2011).
   PubMed Web of Science ®Google Scholar
• Wilson D, Mbhele L, Badri M et al. Evaluation of the World Health Organization algorithm for the diagnosis of HIV-associated sputum smear-negative tuberculosis. Int. J. Tuberc. Lung Dis.15(7), 919–924 (2011).
   PubMedGoogle Scholar
• Havlir D, Ive P, Kendall M et al. International randomized trial of immediate vs early ART in HIV+ patients treated for TB: ACTG 5221 STRIDE Study. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, February 27–March 2 2011.
   Google Scholar
• Karim SA, Naidoo K, Padayatchi N et al. Optimal timing of ART during TB therapy: findings of the SAPiT Trial. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, February 27–March 2 2011.
   Google Scholar
• Franke MF, Robins JM, Mugabo J et al. Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort study. PLoS Med.8(5), e1001029 (2011).
   PubMed Web of Science ®Google Scholar
• Torok ME, Yen NT, Chau TT et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin. Infect. Dis.52(11), 1374–1383 (2011).
   PubMed Web of Science ®Google Scholar
• Lawn SD, Wood R. Poor prognosis of HIV-associated tuberculous meningitis regardless of the timing of antiretroviral therapy. Clin. Infect. Dis.52(11), 1384–1387 (2011).
   PubMed Web of Science ®Google Scholar
• Worodria W, Massinga-Loembe M, Mazakpwe D et al. Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy. J. Acquir. Immu. Defic. Syndr.58(1), 32–37 (2011).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Stop TB Dept., World Health Organization. Dept. of HIV/AIDS. Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. World Health Organization, Geneva, Switzerland (2011).
   Google Scholar
• Fenner L, Forster M, Boulle A et al. Tuberculosis in HIV programmes in lower-income countries: practices and risk factors. Int. J. Tuberc. Lung Dis.15(5), 620–627 (2011).
   PubMedGoogle Scholar
• Smith BM, Menzies D. Treatment of latent TB: first do no harm. Expert Rev. Anti. Infect. Ther.9(5), 491–493 (2011).
   PubMed Web of Science ®Google Scholar
• Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochr. Datab. Syst. Rev.1, CD000171 (2010).
   PubMed Web of Science ®Google Scholar
• Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin. Infect. Dis.50(3), 291–322 (2010).
   PubMed Web of Science ®Google Scholar
• Meya DB, Manabe YC, Castelnuovo B et al. Cost–effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin. Infect. Dis.51(4), 448–455 (2010).
   PubMed Web of Science ®Google Scholar
• Kendi C, Penner J, Otieno B et al. Routine cryptococcal screening and treatment in Kenya: outcomes after six months of follow-up. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 17–20 July 2011.
   Google Scholar
• Jarvis JN, Percival A, Bauman S et al. Evaluation of a novel point of care cryptococcal antigen (CRAG) test on serum, plasma and urine from patients with HIV-associated cryptococcal meningitis. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 17–20 July 2011.
   Google Scholar
• Lindsley MD, Mekha N, Baggett HC et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin. Infect. Dis.53(4), 321–325 (2011).
   PubMed Web of Science ®Google Scholar
• Lin TY, Yeh KM, Lin JC, Wang NC, Peng MY, Chang FY. Cryptococcal disease in patients with or without human immunodeficiency virus: clinical presentation and monitoring of serum cryptococcal antigen titers. J. Microbiol. Immunol. Infect.42(3), 220–226 (2009).
   PubMedGoogle Scholar
• Kisenge PR, Hawkins AT, Maro VP et al. Low CD4 count plus coma predicts cryptococcal meningitis in Tanzania. BMC Infect. Dis.7, 39 (2007).
   PubMedGoogle Scholar
• Makadzange AT, Ndhlovu CE, Takarinda K et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin. Infect. Dis.50(11), 1532–1538 (2010).
   PubMed Web of Science ®Google Scholar
• Bicanic T, Meintjes G, Wood R et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin. Infect. Dis.45(1), 76–80 (2007).
   PubMed Web of Science ®Google Scholar
• Nussbaum JC, Jackson A, Namarika D et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin. Infect. Dis.50(3), 338–344 (2010).
   PubMed Web of Science ®Google Scholar
• Hoffmann CJ, Fielding KL, Charalambous S et al. Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. AIDS24(11), 1709–1716 (2010).
   PubMed Web of Science ®Google Scholar
• Walker AS, Ford D, Gilks CF et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet375(9722), 1278–1286 (2010).
   PubMed Web of Science ®Google Scholar
• Lin D, Li WK, Rieder MJ. Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole. Cochrane Database Syst. Rev.2, CD005646 (2007).
   Google Scholar
• Chung MH, Richardson BA, Tapia K et al. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med.8(3), e1000422 (2011).
   PubMed Web of Science ®Google Scholar
• Rueda S, Park-Wyllie LY, Bayoumi AM et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst. Rev.3, CD001442 (2006).
   PubMedGoogle Scholar